Toshimi Takano

22PUBLICATIONS
125CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthPredictive and prognostic markersMolecular targetsExercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Sep 11, 2026
Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.

|Sep 02, 2026
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.

|Jan 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

Masato Takahashi, Hirofumi Mukai, Toshimi Takano

|Dec 05, 2025
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.

Meiko Nishimura, Takayuki Kobayashi, Yosuke Aoyama

|Nov 04, 2025
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy.

Kazuki Nozawa, Masataka Sawaki, Yukari Uemura

|Jan 24, 2025
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji

Pageof 4

Frequent Collaborators

6 joint publications

Norikazu Masuda

5 joint publications

Takayuki Ueno

3 joint publications

Yosuke Aoyama

3 joint publications

Tomoyuki Aruga